WillItSurvive
Medical technology and health companies · subsidiary of GHV Advanced Health Pvt Ltd · India

Pristyn Care

Indian chain connecting patients to surgeons for hernia, piles, and other elective surgeries.

Losing its protection
Assessed 30 July 2026 · Evidence as of 30 July 2026
The structural protection is eroding.
On the recordSince 30 July 2026 · Checkable from Q1 2026 · Every call on the record Checkpoint: FY25 (ended March 2025) financial filings surface, showing whether losses fell ~60% as guided
The call

Pristyn Care has real patient volume and hospital reach, but seven years in it still loses more than half of every rupee it earns.

Pristyn Care connects patients needing elective surgery with partner hospitals and doctors, handling scheduling and payments online to make surgery easier to find and book. The problem is that each patient is a one-time customer who costs a lot to find through ads, and once their surgery is done, they never come back, so the company burns through cash and has not turned a profit in seven years despite ₹600 crore in yearly sales. Large hospital chains like Apollo, Fortis, and Manipal can simply build their own patient-finding websites and keep all the money themselves, so Pristyn Care has no special protection. The one thing that could matter is whether the company actually raised the $100 million it was chasing in early 2025 at a good price, and whether it finally stopped losing so much money in FY25.

Why
01
AI pressure: AI search and chat tools (Google AI Overviews, ChatGPT) answering symptom queries directly. If patients get surgery answers straight from AI chat instead of clicking ads, Pristyn's paid lead-gen funnel gets more expensive to fill. Could AI do the core job? Unlikely.
02
Bigger players: Apollo Hospitals (Apollo 24/7), Fortis Healthcare, Manipal Health Enterprises. Apollo 24/7 already runs a digital front door into Apollo's own surgeons and hospitals, copying the lead-to-surgery model Pristyn built. Could a giant copy it? Yes, easily.
03
What protects it. 700 to 800 partner hospitals and 400 plus surgeons give Pristyn scale and city coverage big chains have not matched in this specific elective-surgery lead business.
What would change this call
Whether the ~$100M funding round in talks since Jan 2025 closes, and at what share price. A flat or down-priced close would show investor caution; an up-priced close would show renewed confidence.
FY25 (ended March 2025) financial results showing revenue and net loss figures once filed. Losses still near ₹300-380 Cr on higher revenue would show the model still doesn't pay for itself.
Any Fortis, Manipal or Apollo 24/7 launch of a branded elective-surgery digital vertical with real patient volume. Would show incumbents directly replicating Pristyn's model from a position of stronger trust and distribution.
Key numbers
  • FY24 revenue about Rs 601 Cr, up 33% YoY (2024-12-30)
  • FY24 net loss Rs 381 Cr, about 63% of revenue (2025-02-25)
  • July 2025 $4M raise closed at flat share price (2025-07-23)
Named risks
  • Net loss stuck near Rs 381 Cr (63% of FY24 revenue) despite 7 years of operation. Severity: high
  • July 2025 funding round priced flat versus prior round, signaling investor caution. Severity: medium
  • No structural barrier stops large hospital chains from copying the asset-light surgery model. Severity: high
  • Repeated layoffs in 2023 and 2024 indicate ongoing cost-discipline pressure. Severity: medium
  • Pivot to owned hospitals raises capital intensity and moves into incumbents' zone of strength. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Fortis HealthcarecontestingLarge hospital chain with capital to copy elective-surgery vertical, not yet launched as of 2026-07
Manipal Health EnterprisescontestingBed capacity and brand exceed Pristyn's asset-light network as of 2026
Apollo Hospitals (Apollo 24/7)gaining onExpanded Google Cloud partnership for digital healthcare, reported 2025-08-22
Glamyo HealthcontestingDirect clone of Pristyn's elective-surgery model, identified by Pitchbook 2026
RG Stone Urology and Laparoscopy HospitalcontestingDirect India competitor in urology/laparoscopy segment per Pitchbook 2026
Questions people ask
Is Pristyn Care profitable in 2026?
No. Pristyn Care posted a net loss of about Rs 381 Cr on revenue of Rs 600-632 Cr in FY24, roughly flat versus the FY23 loss of Rs 382.6 Cr, per ROC filings reported 2025-02-25. FY25/FY26 audited results confirming a turnaround have not surfaced publicly.
Who owns Pristyn Care?
Pristyn Care is privately held. As of a November 2025 captable, Sequoia Capital (Peak XV) holds the largest single stake at about 23.4%, founders Harsimarbir Singh, Dr. Vaibhav Kapoor and Dr. Garima Sawhney collectively hold about 48.1%, and other investors hold roughly 45.9%.
Who is Pristyn Care's biggest competitor?
Direct clone Glamyo Health competes on the same asset-light elective-surgery model, while large Indian hospital chains Fortis, Manipal Health Enterprises and Apollo Hospitals (via its Apollo 24/7 digital arm) have the beds, brand and capital to replicate Pristyn's playbook at any time.
Could AI replace Pristyn Care?
Not the core business. Physical surgery, licensed surgeons, hospital beds and insurance/regulatory rails cannot be automated away. AI is only exposed at the administrative front-end (triage, eligibility checks), and Pristyn Care itself deploys AI there via tools like Mira.AI (launched June 2023) and its Innovation Lab (launched August 2024).
Did Pristyn Care raise $100 million in 2025?
Not confirmed. Pristyn Care was reportedly in talks for a roughly $100M raise as of January 2025 targeting an H1 2025 close, but public records only show a small $4M extension closing on 2025-07-23 at the same per-share price as the prior round, signaling investor caution rather than a full raise.
What is Pristyn Care's valuation as of 2026?
Roughly $1.2-1.4B, unchanged since it became a unicorn in December 2021 via a $96M Series E led by Sequoia Capital India. Its most recent disclosed raise, a $4M extension on 2025-07-23, priced at the same Rs 10,038/share as the prior round, i.e. flat, not up.
Timeline
  • 2025-09Acquired Laparo Obeso Centre, a Pune bariatric surgery center
  • 2025-07-23Raised $4M extension at flat share price of Rs 10,038
  • 2025-01-02Reportedly in talks to raise ~$100M for expansion and tech
  • 2024-08Launched Pristyn Care Innovation Lab (PCIL) for AI R&D
  • 2024-05Used Apple Vision Pro-assisted bariatric and orthopedic surgery
  • 2024-03-01Laid off ~120 staff, exited 6 cities and 3 service categories
  • 2023-06Launched Mira.AI training tool for care coordinators
  • 2023-04Deployed CUVIS AI-assisted robotic joint-replacement system
  • 2023-03Cut ~300 employees amid healthtech sector downturn
  • 2021-12Became India's 4th healthtech unicorn via $96M Series E
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources